Sarah Kennedy, PhD, is the Executive Director, Medical Affairs, at Biosplice Therapeutics. Biosplice is currently developing a novel small molecule, lorecivivint, as a potential treatment for knee osteoarthritis. Sarah’s interests include clinical trial design, mechanisms of pain in osteoarthritis, and factors affecting osteoarthritis disease progression.
